Breaking News Instant updates and real-time market news.

CLVS

Clovis

$34.76

-0.59 (-1.67%)

16:38
10/04/16
10/04
16:38
10/04/16
16:38

Clovis Oncology, Lonza enter manufacturing services pact for rucaparib

On October 3, Clovis Oncology and Lonza entered into a manufacturing services agreement for the long term manufacture and supply of the active pharmaceutical ingredient for rucaparib, according to a regulatory filing. The terms and conditions of the agreement are contingent upon the approval by the U.S. Food and Drug Administration of the initial New Drug Application for rucaparib, unless triggered earlier by Clovis. Clovis and Lonza are parties to a development and manufacturing agreement, dated February 8, 2013, as amended, under which Lonza has supplied rucaparib API for clinical development. The agreement provides that Lonza will be a non-exclusive manufacturer of the rucaparib API during the term of the agreement, which expires on December 31, 2025, unless extended by mutual written consent of the parties. Under the agreement, Lonza will construct, in an existing Lonza facility, a production train that will be exclusively dedicated to the manufacture of the rucaparib API. The dedicated production train will provide manufacturing capacity to meet Clovis' currently anticipated needs for commercial supply of rucaparib API. Clovis is obligated to make scheduled capital program fee payments towards capital equipment and other costs associated with the construction of the dedicated production train and, once the facility is operational, Clovis is obligated to pay a fixed facility fee each quarter for the duration of the agreement. Pursuant to the terms of the agreement, Lonza will manufacture and store an advanced intermediate to be used in the subsequent production of the rucaparib API. Clovis will pay fixed fees on a per kilogram basis for quantities of the advanced intermediate and the rucaparib API ordered by Clovis under the agreement, subject to certain adjustments. Until the dedicated facility is completed and operationally qualified, Lonza will manufacture the rucaparib API in existing Lonza facilities at pricing established in the agreement.

  • 06

    Nov

  • 23

    Feb

CLVS Clovis
$34.76

-0.59 (-1.67%)

09/21/16
09/21/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Monsanto (MON) upgraded to Overweight from Neutral at JPMorgan with analyst Jeffrey Zekauskas saying the risk in the shares is "less than what the market assumes." 2. Barclays (BCS) upgraded to Buy from Hold at HSBC citing the pending disposal of non-core businesses and resulting value creation. 3. Etsy (ETSY) upgraded to Buy from Neutral at Monness Crespi with the firm's analyst believing that Etsy shares can still move higher and sees a solid opportunity for upward revisions from improving conversion rates due to enhanced search and mobile functionality, expanding take rates, and advanced cross-boarder commerce capabilities with vendors. 4. Clovis (CLVS) upgraded to Outperform from Neutral at Credit Suisse with analyst Kennen MacKay saying the potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition." 5. Jabil Circuit (JBL) upgraded to Buy from Neutral at UBS with analyst Steven Milunovich saying the company's cash flow is nearing an inflection amid an upturn in its Apple (AAPL) business. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/21/16
JANY
09/21/16
DOWNGRADE
JANY
Neutral
Clovis downgraded to Neutral from Buy at Janney Capital
09/21/16
JANY
09/21/16
DOWNGRADE
Target $36
JANY
Neutral
Janney downgrades Clovis with buyout speculation at 'fever pitch'
Janney Capital analyst Roy Buchanan downgraded Clovis Oncology (CLVS) to Neutral from Buy with an increased fair value estimate of $36. Clovis is up 17c to $35.00 in late morning trading. In a research note partially titled, "May Be Right, May Be Crazy - M&A Speculation At Fever Pitch," Buchanan says there is a "finite chance" that Clovis will need to market its PARP inhibitor rucaparib by itself. He believes a late-2016 approval for rucaparib is likely. The analyst attributes his increased fair value estimate to "acquisition optionality." Reports of Takeda's (TKPYY) reserving up to $15B for acquisitions and Medivation's (MDVN) takeout have given Clovis shares a lift, Buchanan tells investors. The analyst adds that rumors surfaced yesterday of potential interest in the company from Eli Lilly (LLY).
10/04/16
PIPR
10/04/16
NO CHANGE
Target $42
PIPR
Neutral
Clovis price target raised to $42 from $14 at Piper Jaffray
Piper Jaffray analyst Steven Breazzano raised his price target for Clovis Oncology (CLVS) to $42 after taking a "comprehensive look" at the PARP inhibitor landscape in ovarian cancer and beyond. The company's PARP inhibitor rucaparib has demonstrated an active profile in ovarian cancer and all signs point to an approval in the 3L+ setting early next year, Breazzano tells investors in a research note. The analyst, however, believes the ultimate key is success in the earlier maintenance setting, and he thinks the race may still be Tesaro's (TSRO) niraparib's to lose. Breazzano keeps a Neutral rating on Clovis.

TODAY'S FREE FLY STORIES

MRSN

Mersana Therapeutics

21:10
06/27/17
06/27
21:10
06/27/17
21:10
Syndicate
Mersana Therapeutics 5M share IPO priced at $15.00 »

The deal priced in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

BLUE

bluebird bio

$106.90

-4.2 (-3.78%)

21:09
06/27/17
06/27
21:09
06/27/17
21:09
Syndicate
bluebird bio 3.81M share Secondary priced at $105.00 »

Goldman Sachs,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

ADNT

Adient

$63.20

-1.63 (-2.51%)

20:25
06/27/17
06/27
20:25
06/27/17
20:25
Conference/Events
Adient to hold a meeting »

EVP & CFO Stafeil,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 27

    Jul

GIS

General Mills

$55.52

-0.65 (-1.16%)

, MON

Monsanto

$117.25

-0.55 (-0.47%)

20:25
06/27/17
06/27
20:25
06/27/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

GIS

General Mills

$55.52

-0.65 (-1.16%)

MON

Monsanto

$117.25

-0.55 (-0.47%)

PAYX

Paychex

$58.62

-0.62 (-1.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 28

    Jun

  • 12

    Jul

AAPL

Apple

$143.73

-2.09 (-1.43%)

19:32
06/27/17
06/27
19:32
06/27/17
19:32
Periodicals
Apple looks to hire 'Siri Event Maven,' 9to5Mac reports »

An Apple job listing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOSBF

Toshiba, also use TOSYY

$2.60

-0.09 (-3.35%)

, TOSYY

Toshiba, also use TOSBF

$15.67

-0.24 (-1.51%)

19:22
06/27/17
06/27
19:22
06/27/17
19:22
Periodicals
Toshiba to face holder wrath after failing to sell chip unit, Reuters says »

Toshiba is anticipated to…

TOSBF

Toshiba, also use TOSYY

$2.60

-0.09 (-3.35%)

TOSYY

Toshiba, also use TOSBF

$15.67

-0.24 (-1.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$150.58

-3.01 (-1.96%)

19:21
06/27/17
06/27
19:21
06/27/17
19:21
Periodicals
Facebook previously explored effort to promote flu shots, CNBC reports »

Facebook was working with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

AAPL

Apple

$143.73

-2.09 (-1.43%)

19:15
06/27/17
06/27
19:15
06/27/17
19:15
Hot Stocks
Munster lays out five-year Apple model, sees 'Apple Glasses' wearable in 2020 »

Gene Munster, a longtime…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$927.33

-24.94 (-2.62%)

, GOOGL

Alphabet Class A

$948.09

-24 (-2.47%)

19:02
06/27/17
06/27
19:02
06/27/17
19:02
Hot Stocks
Senator urges FTC oversight of Google in wake of Europe fine »

Senator Richard…

GOOG

Alphabet

$927.33

-24.94 (-2.62%)

GOOGL

Alphabet Class A

$948.09

-24 (-2.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

APO

Apollo Global

$25.90

-0.33 (-1.26%)

18:58
06/27/17
06/27
18:58
06/27/17
18:58
Periodicals
Apollo Global hits record-breaking $23.5B target for buyout fund, WSJ says »

Private equity firm…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QCOM

Qualcomm

$55.43

-1.13 (-2.00%)

18:54
06/27/17
06/27
18:54
06/27/17
18:54
Periodicals
Judge says FTC suit against Qualcomm can proceed, Reuters reports »

A federal judge ruled…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LNEGY

Linde

$19.25

0.08 (0.42%)

18:53
06/27/17
06/27
18:53
06/27/17
18:53
Periodicals
Linde unit agrees to $20M settlement deal in whistleblower case, Reuters says »

Linde's Lincare…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCHC

HC2 Holdings

$5.82

0.03 (0.52%)

18:50
06/27/17
06/27
18:50
06/27/17
18:50
Hot Stocks
HC2 Holdings subsidiary to acquire major interest in DTVA »

HC2 Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$65.54

-0.38 (-0.58%)

18:38
06/27/17
06/27
18:38
06/27/17
18:38
Periodicals
Merck's cholesterol drug anacetrapib could serve as catalyst, Barron's reports »

Merck announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

TROX

Tronox

$13.52

-0.25 (-1.82%)

18:37
06/27/17
06/27
18:37
06/27/17
18:37
Hot Stocks
Tronox elects Kaufthal as non-executive chairman »

Tronox announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANCUF

Alimentation Couche-Tard

$49.16

1.0803 (2.25%)

, CST

CST Brands

$48.53

-0.01 (-0.02%)

18:19
06/27/17
06/27
18:19
06/27/17
18:19
Hot Stocks
Alimentation Couche-Tard cleared in Canada for acquisition of CST Brands »

Alimentation Couche-Tard…

ANCUF

Alimentation Couche-Tard

$49.16

1.0803 (2.25%)

CST

CST Brands

$48.53

-0.01 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSLI

Merus Labs

$1.23

-0.0015 (-0.12%)

18:01
06/27/17
06/27
18:01
06/27/17
18:01
Hot Stocks
Merus Labs reminds shareholders to vote for arrangement with Norgine »

Merus Labs International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EIGI

Endurance

$8.20

-0.15 (-1.80%)

18:01
06/27/17
06/27
18:01
06/27/17
18:01
Hot Stocks
Endurance chief administration officer Andreasen to leave company »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HII

Huntington Ingalls

$186.97

0.68 (0.37%)

17:41
06/27/17
06/27
17:41
06/27/17
17:41
Hot Stocks
Huntington Ingalls receives contract modifications to incorporate upgrades »

Huntington Ingalls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IP

International Paper

$56.18

-0.55 (-0.97%)

17:34
06/27/17
06/27
17:34
06/27/17
17:34
Hot Stocks
International Paper agrees to settle Kleen Products class action litigation »

International Paper…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HUSA

Houston American Energy

$0.67

0.0385 (6.10%)

17:33
06/27/17
06/27
17:33
06/27/17
17:33
Syndicate
Houston American Energy requests withdrawal of registration statement »

The company determined…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KBH

KB Home

$22.82

0.04 (0.18%)

, RYI

Ryerson

$9.00

-0.1 (-1.10%)

17:24
06/27/17
06/27
17:24
06/27/17
17:24
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: KB…

KBH

KB Home

$22.82

0.04 (0.18%)

RYI

Ryerson

$9.00

-0.1 (-1.10%)

AVAV

AeroVironment

$32.49

1.52 (4.91%)

CAMP

CalAmp

$19.25

-0.37 (-1.89%)

GMRE

Global Medical REIT

$9.83

0.07 (0.72%)

WLL

Whiting Petroleum

$5.48

0.04 (0.74%)

OAS

Oasis Petroleum

$7.93

0.21 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 27

    Jun

  • 27

    Jun

  • 27

    Jun

  • 03

    Jul

  • 04

    Jul

  • 05

    Jul

  • 28

    Jun

CHKE

Cherokee

17:22
06/27/17
06/27
17:22
06/27/17
17:22
Hot Stocks
Breaking Hot Stocks news story on Cherokee »

Cherokee says announcing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

KBH

KB Home

$22.82

0.04 (0.18%)

17:16
06/27/17
06/27
17:16
06/27/17
17:16
Hot Stocks
KB Home sees Q3 housing revenue $1.08B-$1.15B »

Sees Q3 average selling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

KBH

KB Home

$22.82

0.04 (0.18%)

17:16
06/27/17
06/27
17:16
06/27/17
17:16
Hot Stocks
KB Home raises FY17 housing revenue view to $4.2B-$4.4B from $4B-$4.3B »

Sees FY17 average selling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.